HCW Biologics Gets FDA Clearance to Proceed With Cancer-Treatment Trial
October 28 2021 - 7:51AM
Dow Jones News
By Chris Wack
HCW Biologics Inc. said it has been cleared by the U.S. Food and
Drug Administration to proceed to evaluate its lead drug candidate,
HCW9218, in a first-in-human Phase 1b clinical trial in patients
with advanced pancreatic cancer.
The biopharmaceutical company said its HCW9218 is an injectable,
fusion protein complex designed to drive bifunctional, anti-tumor
activity by activating desired immune responses to attack cancer
cells while simultaneously blocking unwanted immunosuppressive
activities.
HCW said that in preclinical studies, it showed that HCW9218
enhanced the anti-tumor efficacy of chemotherapy docetaxel and
gemcitabine plus nab-paclitaxel against melanoma and pancreatic
cancer, respectively, and simultaneously alleviated the off-target,
unwanted effects of chemotherapies on normal tissues.
In experimental animal models, HCW9218 was also shown to augment
anti-tumor activities of therapeutic and checkpoint antibodies,
which are currently standard-of-care anti-cancer treatment for
certain solid tumors.
HCW Biologics shares were up 12%, to $3.28, in premarket
trading.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
October 28, 2021 07:36 ET (11:36 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
HCW Biologics (NASDAQ:HCWB)
Historical Stock Chart
From Aug 2024 to Sep 2024
HCW Biologics (NASDAQ:HCWB)
Historical Stock Chart
From Sep 2023 to Sep 2024